PMID- 23428919
OWN - NLM
STAT- MEDLINE
DCOM- 20130426
LR  - 20191112
IS  - 1349-3299 (Electronic)
IS  - 1349-2365 (Linking)
VI  - 54
IP  - 1
DP  - 2013
TI  - Clinical status and outcome of Japanese heart failure patients with reduced or 
      preserved ejection fraction treated with carvedilol.
PG  - 15-22
AB  - The effect of beta-blockers in treating Japanese heart failure (HF) patients with 
      preserved left ventricular (LV) ejection fraction (EF) is unclear. This 
      prospective observational study enrolled 1,682 Japanese HF patients who received 
      carvedilol for the first time. Patients were followed for a mean of 1.6 years. 
      The 1,492 patients with baseline LVEF measurements were allocated to the 
      following groups: reduced EF (LVEF < 40%; n = 724), borderline EF (LVEF 4050%; n 
      = 355), and preserved EF (LVEF >/= 50%; n = 413). Baseline characteristics, New 
      York Heart Association (NYHA) class, change in B-type natriuretic peptide (BNP) 
      level, and long-term outcome were compared among the groups. Patients with 
      preserved EF were more likely to be older, female, and have ischemic etiology and 
      hypertension than patients with reduced EF. Carvedilol maintenance dosage was 
      lower in patients with preserved EF (7.9 mg/day versus 6.6 mg/ day). NYHA class 
      and BNP level were lower in patients with preserved EF at baseline but improved 
      to the same level in all groups at 6 months. After adjusting for baseline 
      characteristics, the hazard ratio for death or hospitalization due to 
      cardiovascular disease in patients with preserved EF versus those with reduced EF 
      was 1.031 (P = 0.847). This study elucidated the characteristics of HF patients 
      given carvedilol in "real world" clinical settings. A comparative controlled 
      study is necessary to elucidate whether the improvements in NYHA and BNP as well 
      as the outcome profile observed in patients with preserved EF were caused by the 
      favorable effects of carvedilol.
FAU - Mori, Yoshihiro
AU  - Mori Y
AD  - Department of Post-Marketing Studies Management, Daiichi Sankyo Co., Ltd., Tokyo, 
      Japan.
FAU - Nishikawa, Yasuhiro
AU  - Nishikawa Y
FAU - Kobayashi, Fumiaki
AU  - Kobayashi F
FAU - Hiramatsu, Katsutoshi
AU  - Hiramatsu K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Int Heart J
JT  - International heart journal
JID - 101244240
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adrenergic beta-Antagonists/administration & dosage/adverse effects
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - *Carbazoles/administration & dosage/adverse effects
MH  - Carvedilol
MH  - Drug Monitoring/statistics & numerical data
MH  - Female
MH  - *Heart Failure/blood/diagnosis/drug therapy/epidemiology/etiology/physiopathology
MH  - Humans
MH  - Japan/epidemiology
MH  - Male
MH  - Medication Therapy Management
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Pharmacovigilance
MH  - Prognosis
MH  - *Propanolamines/administration & dosage/adverse effects
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Sex Factors
MH  - Stroke Volume/*drug effects
MH  - Time
MH  - Treatment Outcome
EDAT- 2013/02/23 06:00
MHDA- 2013/04/27 06:00
CRDT- 2013/02/23 06:00
PHST- 2013/02/23 06:00 [entrez]
PHST- 2013/02/23 06:00 [pubmed]
PHST- 2013/04/27 06:00 [medline]
AID - DN/JST.JSTAGE/ihj/54.15 [pii]
AID - 10.1536/ihj.54.15 [doi]
PST - ppublish
SO  - Int Heart J. 2013;54(1):15-22. doi: 10.1536/ihj.54.15.